Gosselies, Belgium — October 7, 2025 — Leads & Copy — Bioxodes SA has appointed Philippe Monteyne, MD, PhD, as chairman of its Board of Directors. Dr. Monteyne, a neurologist with experience as a life sciences investor and pharmaceutical executive, will guide the company as it advances BIOX-101, a novel therapy for stroke, through clinical trials. The appointment follows encouraging Phase 2a interim data for BIOX-101 in intracerebral hemorrhage. A Phase 2b trial is scheduled to begin in 2027.
Marc Dechamps, CEO of Bioxodes, expressed enthusiasm for Dr. Monteyne’s appointment and acknowledged Pierre Detrixhe’s contributions as the company’s previous chairman.
Dr. Monteyne is Senior Advisor for Life Sciences at AltamarCAM Partners. He held senior positions at SmithKline Beecham, GSK and Sanofi. At GSK, he was responsible for the development and launch of the company’s cervical cancer vaccine Cervarix.
Bioxodes is preparing for a potentially registrational global multi-center Phase 2b trial for BIOX-101 in patients who suffered intracerebral hemorrhage (ICH). The recombinant peptide will also be developed to treat acute ischemic stroke.
In September, Bioxodes announced encouraging second interim results from its BIRCH Phase 2a clinical trial, confirming the breakthrough potential of BIOX-101. All patients treated with the candidate experienced a reduction in hematoma, a finding supported by biomarker measurements, all of which trended in support of the clinical observations.
BIOX-101 is a proprietary recombinant version of a small protein found in the saliva of the tick (Ixodes ricinus). It is designed to inhibit the harmful secondary effects of hemorrhagic stroke such as secondary ischemia, neuroinflammation and neuronal damage.
Contact:
Alexandra Schiettekatte
communication@bioxodes.com
+32 476 65 04 38
Source: Bioxodes SA
